News AZ's Etcamah falls short in first-line breast cancer trial A week after getting FDA approval for frontline breast cancer treatment, AstraZeneca's Etcamah missed the mark in a trial aiming to expand its label.
Oncology How today’s biotechs are helping us Stand Up To Cancer In recognition of Stand Up To Cancer Day, a look at next-generation treatments that are on the verge of making it into clinical practice.
News Bayer moves Hyrnuo into frontline lung cancer treatment Bayer chases after Boehringer with an FDA approval for oral HER2 inhibitor Hyrnuo in previously untreated HER2+ lung cancer.
News Amgen's Imdelltra scores again in small cell lung cancer Amgen's Imdelltra and AstraZeneca's Imfinzi have improved survival compared to Imfinzi alone as first-line maintenance treatment for ES-SCLC.
News BMS eyes role for new CAR-T in post-BCMA multiple myeloma BMS' arlo-cel has shown activity in a trial that could underpin filings in multiple myeloma settings where the four main drug classes have failed.
News FDA overrides adcomm and approves AZ's oral SERD The FDA has gone against the advice of its own expert advisors and approved AstraZeneca's Etcamah as a frontline treatment for breast cancer.
News Telix to buy radiopharma rival ITM for $1.65bn upfront Telix Pharma has reached a deal to acquire ITM, extending a wave of consolidation in the radiopharma category over the last couple of years.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.